

State of Illinois Drugs and Therapeutics Advisory Board

Minutes for January 11, 2024 Meeting

- I. Dr. Patel opened the meeting at 8:38am.
- II. Roll Call was taken.
- III. No conflicts of interest.
- IV. The October 5, 2023, meeting minutes were unanimously approved.
- V. Product: Vyjuvek
Presented by: Laura A. Niewiadomski, Senior National Director, Field Medical Affairs

Presented Material Highlights:
 - Gene therapy topical for Dystrophic ED.
 - Approval was a full approval.
 - Approval based on complete wound healing.
 - Secondary endpoint was also met.
Discussion Highlights:
 - Three requests for this in the past year.
 - Prevalence is 1-3:1,000,000.
 - First treatment for very rare disease.
Motion: Garry Moreland moved to leave non-preferred.
Second: Dr. Goyal
Motion passed with no dissent.
- VI. PDL Drug Appeals
 - None for this meeting.
- VII. New Drug Appeals
 - None for this meeting.
- VIII. Class Reviews
 - a. Topic: Insulin
Presented by: Jen Phillips, PharmD

Presented Material Highlights:
 - Last reviewed in 2017.
 - Detemir is being discontinued.

- Guideline recommend have short, intermediate, long-acting and fixed dose formulations on formulary.
- Biosimilars are now available.
- Insulin is the standard of care for Type 1 diabetes.
- Long-acting products are preferred.
- Reserved for Type 2 diabetics after failure on other agents.
- ADA does not specify preferred products.

Discussion Highlights:

- Lantus is preferred insulin glargine at time of review.
- Patients on degludec = ~700.
- Pharmacies have no issues with insulin coverage at this time.
- All insulins took a 75% price reduction.
- Interesting marketplace right now.
- Would like as much choice as possible in case of product shortages.
- Add degludec choice to preferred products.
- Providers will need to move detemir patients to another long-acting products.
- Not a one-to-one conversion.

Motion: Garry Moreland moved to make a formulation of degludec preferred and leave other formulations as is.

Second: Dr. Goyal

Motion passed without dissent.

Dr. Goyal abstained.

b. Topic: DPP-4 Inhibitors

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Last reviewed 2017.
- Linagliptin will be available generically in 2025.
- Onglyza is discontinued.
- 2nd or 3rd line treatments.
- Selected niche so at least one preferred.
- Compared with other classes no cardio-renal protective qualities and equal or less A1C decreases.
- Less side effects but better as adjunct therapy.
- Saxagliptin can cause increased hospitalization for heart failure.
- All available as combination products with Metformin and some with other agents.

Discussion Highlights:

- Only for patients where there is concern for increased hypoglycemia.

Motion: Garry Moreland moved to leave class as is.

Second: Dr. Shaw

Motion passed without dissent.

- c. Topic: SGLT-2 Inhibitors
Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Cardiovascular decrease in heart failure death.
- Empagliflozin has expanded cardiovascular protection as well.
- Can be 1st line in Type 2 diabetes.
- Metformin and second agent are recommended as first line and can include SGLT2 agents.
- 2023 ADA guidelines are geared towards either cardiovascular or weight loss goals.
- Cardiorenal issues should be treated with these agents.
- Agents can be used even in the absence of diabetes.
- Decrease hospitalization for heart failure.

Discussion Highlights:

- Will the combination products increase adherence?
- Possibly make a combination product preferred.
- One of these with Metformin may be beneficial to make preferred.
- Which is the best combination to move?
- Maybe make combination product preferred with PA.
- May need to discuss further.
- Polypharmacy maybe a concern.
- Table motion for more discussion at a different time.
- If a physician is concerned with adherence, then they can request a combination product.
- Utilization is low.
- More information needed about adherence of 2 separate agents versus a single combination agent.
- Data on poor control of diabetes and adherence as the issue.
- Is polypharmacy an issue?
- Is there an increase in drug-drug interactions?
- Any other safety concerns?
- Four prescription policy is also a concern for pharmacies.
- Add to agenda for the next meeting. Send information with clinical information for the April meeting.

Motion: Dr. Vergara-Rodriguez moved to make Xigduo XR, Synjardy XR and Invokamet XR preferred with PA.

Second: Garry Moreland.

Motion: Dr. Goyal moves to table until more information can be supplied.

Second: Dr. Patel.

Motion to table takes precedent.

Motion is passed by a 3-2 vote. This issue will be further studied and brought back for further consideration. Board is encouraged to share any information they may have.

Motion: Dr. Patel moves to leave as is until next meeting and further discussion.

Second: Dr. Vergara-Rodriguez.

Motion passed without dissent.

IX. New Drug Initial Reviews

- Product: Olpruva

Presented by: Jen Phillips, PharmD and Adrian Quartel, Chief Medical Officer at Zevra Therapeutics

Presented Material Highlights:

- Dual coated sodium phenylbutyrate for oral suspension.
- All sodium phenylbutyrate are the same and personal choice on dosage should be available.

Discussion Highlights:

- HFS has 2 current patients on these products.
- No efficacy studies were performed for Olpruva. The coating is designed to make it more palatable.
- Generics are available.

Motion: Dr. Patel moved to leave Olpruva non-preferred.

Second: Dr. Goyal

Motion passed without dissent.

- Product: Emflaza

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Corticosteroid approved only for DMD patients.
- Indicated for 2 years and older.
- Endpoint was muscle strength measurement.
- Prednisone has more weight gain than Emflaza.
- Prednisone also works.
- Emflaza showed 27.9% vs 34.9% in prednisone group showed weight gain.
- 8.8% reported psychiatric behavioral issues with Emflaza vs 14.3% in prednisone.
- Prednisone is recommended with moderate evidence in guidelines.
- Emflaza is recommended with weak evidence in guidelines.
- Actual weight gain Emflaza was 5-6 kg vs 8-9 kg for prednisone.

Discussion Highlights:

- This is still a corticosteroid.
- Not great evidence to support this over prednisone.
- Prednisone has a bit more weight gain. Emflaza can cause cataracts. No percentage of increase in cataracts was noted in trials. One of 51 patients reported discontinuation due to cataracts.

Motion: Dr. Patel moved to leave non-preferred.

Second: Dr. Vergara-Rodriguez.

Motion passed with no dissent.

- Product: Rayaldee
Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Approved for secondary hyperparathyroidism in adult patients with stage 3-4 kidney disease and low Vitamin D levels.
- Guidelines show limited studies on whether this product shows any superiority over Calcitriol.
- Drug interactions do exist.

Discussion Highlights:

- No discussion.

Motion: Dr. Patel moved to leave non-preferred.

Second: Dr. Vergara-Rodriguez.

Motion passed with no dissent.

X. Public Testimony

- None for this meeting.

XI. Provider Review Request

- None at this meeting.

XII. Future Agenda Preview

- Sheri Dolan shared the proposed dates for 2024.
- April 11, 2024
- August 1, 2024
- October 10, 2024

XIII. HFS Update

- New Program.
- State Pharmaceutical Assistance Program for Adult and Senior Immigrants.
- Voluntary for manufacturers.
- Not all manufacturers are participating.
- Pricing structure for Medicaid has changed.
- In an effort to take care of this population and maintain cost effectiveness, we are asking that the Board be open to adding in an additional meeting in the first half of the year.

Motion: Dr. Patel moved to add meeting if necessary.

Second: Dr. Vergara-Rodriguez

Motion passed without dissent.

- XIV. Department Update-Jose Jimenez
- Changes at the Director level and Chief of Staff.
 - Please be patient if things take a little longer than usual.
 - Will provide more information at the next meeting.
- XV. Adjournment-Dr. Patel adjured the meeting at 10:37 am.

Attendees

The names of board members and speakers are bolded.

Panelist List

1. Alyssa Stephenson
2. Sheri Dolan
3. Donna Clay
- 4. Arvind Goyal**
5. Heather Freeman
6. Jennifer Dewitt
7. Jose Jimenez
- 8. Garry Moreland**
9. Claudia Colombo
- 10. Maurice Shaw**
- 11. Pamela Vergara-Rodriguez**
12. Mary Moody
- 13. Mahesh Patel**
14. Melissa Davis
- 15. Steve Sproat**
16. Thomas Dorn
17. Jen Phillips

Attendee List

1. A Meizlik
- 2. Adrian Quartel**
3. Brielle Dozier Artia Solutions
4. Chase Williams
5. Clemice Hurst
6. Dan Sbrilli
7. Doug Johnson
8. Elizabeth Plouff
9. Harry Jordan
10. Heather Pezewski

11. Huzefa Master - Meridian
12. Jason Vandervest - Vertez
13. Joanna Janota
14. John Bullard – Alexion-AstraZaneca Rare Disease
15. Kelly Hamilton
16. Kenneth Ring
17. Kim Witte
- 18. Laura Niewiadomski**
19. Leonard Erskine
20. Libby Brunsvold
21. Mark Friederich
22. Michele Shirley – Indivior
23. Nikki Asse
24. Mike Buege
25. Patrick Lindstrom
26. Pawel Piechocinski
27. Ryan Segroves
28. Steve Patterson
29. Thomas Vayalil
30. Tiawana Parker